Doubts dog new anticoagulant uptake
This article was originally published in Scrip
Executive Summary
Experts are struggling to predict what the pattern of uptake will be of the new oral anticoagulants for the stroke prevention in atrial fibrillation (SPAF) market. While nobody can dispute the need for alternatives to warfarin, there are concerns over the lack of antidotes to reverse bleeding, and ambiguity over the appropriate patient populations to be treated with the latest products.